Peptonic Medical AB har tecknat ett avtal med Fermata Inc. i Japan

Peptonic Medical (publ) (‘Peptonic’ eller ‘bolaget’) annonserar att bolaget tecknat avtal med Fermata Inc. för den japanska marknaden. Avtalet avser VagiVital®️ och Lunette®️. Avtalet gäller registrering och marknadstest av VagiVital®️ och Lunette®️ i Japan. Fermata Inc. har bekräftat att VagiVital®️ registrerats under kosmetisk lagstiftning i Japan och kan börja säljas i september innevarande år. Lunette®️ […]

Peptonic Medical AB has entered into a partnership with Fermata Inc. in Japan

Peptonic Medical (publ) (‘Peptonic’ or ‘the Company’) informs that the company has entered into an agreement with fermata Inc. for the Japan market. The agreement concerns VagiVital®️ and Lunette®️. The agreement concerns early registrations and non-exclusive commercial introduction of VagiVital®️ and Lunette®️ into the Japan market. fermata Inc. has confirmed the regulatory clearance to introduce […]

Peptonic konverterar lån om 7,5 Mkr från Vidarstiftelsen till aktier enligt avtal

Peptonic Medical AB (publ) (“Peptonic” eller “Bolaget”) meddelar idag att man beslutat att utnyttja rätten att konvertera det lån om 7,5 Mkr som Bolaget upptog i november 2020 från Vidarstiftelsen. Detta i enlighet med det låneavtal om undertecknades i maj 2020. Konverteringen sker genom en riktad kvittningsemission till Vidarstiftelsen där betalning för aktierna erläggs genom […]

Peptonic converts loan of SEK 7.5 million from the Vidarstiftelsen foundation to shares

Peptonic Medical AB (publ) (“Peptonic” or “the Company”) announces today that it has decided to exercise the right to convert the loan of SEK 7.5 million that the Company raised in November 2020 from the Vidarstiftelsen foundation. This is in accordance with the loan agreement as signed in May 2020. The conversion takes place through […]

Årsredovisning för verksamhetsåret 2019

Peptonic Medical AB (publ) årsredovisning för verksamhetsåret 2019 finns nu tillgänglig på sidan Financial information. Er tryckt kopia av årsredovisningen kan beställas via e-post info@peptonicmedical.se eller via telefon 0768 550 200. Johan Inborr, VD Telefon: + 46 708 853 893E-post: johan.inborr@peptonicmedical.se Om VagiVital® VagiVital® är en patentsökt hormonfri medicinteknisk produkt för behandling av symtom kopplade till vaginal atrofi (torra slemhinnor […]

Halvårsrapport för perioden januari-juni 2019

2019 kvartal 2 (apr-jun) Omsättning produkter 1 011 (0) KSEK Bruttovinst 768 (0) KSEK, 76% (0%) Rörelseresultat -5 102 (-3,563) KSEK Resultat per aktie -0,06 (-0,04) SEK 2019 första halvåret (jan-jun) Omsättning produkter 2 481 (0) KSEK Bruttovinst 1 570 (0) KSEK, 63% (0%) Rörelseresultat -8 287 (-6,385) KSEK Resultat per aktie -0,09 (-0,07) SEK  VD […]

Interim report January to June 2019

2019 first quarter (Apr-Jun) Net sales of products KSEK 1,011 (0) Gross profit KSEK 768 (0), Gross margin 76% (0%) Operating loss KSEK -5,102 (-3,563)  Loss per share SEK -0.06 (-0.04) 2019 first half year (Jan-Jun) Net sales of products KSEK 2,481 (0) Gross profit KSEK 1,570 (0), Gross margin 63% (0%) Operating loss KSEK […]

Analys Peptonic: Nya pengar för tillväxt

Basscenariot visar på en riktkurs om 1,40 kr, vilket är avsevärt högre än teckningskursen på 0,83 kr i den pågående företrädesemissionen. Läs hela artikeln på aktiespararna.se »Ladda ner analysen (PDF) »

Analysguiden publicerar en ny analys av Peptonic Medical

PEPTONIC Medical (publ) (”PEPTONIC Medical eller ”Bolaget”) – meddelar att Analysguiden med anledning av den pågående företrädesemissionen har publicerat en ny analys av bolaget. Analysguiden är ett oberoende analysföretag som publicerar sina analyser via Aktiespararna. Analysguiden presenterade sin analys av Bolaget den 2:a juni 2017. Analysguiden kan laddas ned som PDF. Ladda ner Analysguiden (PDF) […]

CE-marked non-prescription vaginal gel next goal for Peptonic Medical

The Board of Directors of Peptonic Medical AB (publ) (Peptonic or Company) today announced the decision to commence the process of obtaining CE-marking for the vaginal gel that was used as a placebo in a recently completed 2b study conducted by the Company. Once the CE-mark has been obtained, the Company intends to launch the […]

Informationsmöte den 11/4

Tisdagen den 11 april arrangerade PEPTONIC medical ett informationsmöte med aktieägarna. På mötet berättade styrelse och ledning om den nyss slutförda fas IIb-studien och om planerna framåt. Här nedan presenteras svar på frågor som ställdes på mötet – och en presentation finns också tillgänglig för nedladdning. Presentation från mötet Presentation (PowerPoint) » Presentation (PDF) » Frågor och svar på mötet Johan Inborr, […]

Informationsmöte tisdagen den 11 april 2017

Aktieägarna i Peptonic Medical bjuds härmed in till ett informationsmöte den 11 april kl 17-19. Mötet hålls på Scandic Klara, Slöjdgatan 7, Stockholm. Medverkande från bolagets sida är medlemmar ur styrelsen och ledningen, som berättar om den nyss slutförda studien och om planerna framåt. Vi skulle uppskatta om ni anmäler er i förväg. Anmälan görs […]

Peptonic Medical announces results of the first part of its phase 2b study

Peptonic Medical AB (publ) today announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of vaginal atrophy, were not met. However, further analyses of the study data show that the gel, both without and with the active ingredient (oxytocin), […]

God rekrytering i Peptonic Medical ABs fas 2b studie

Peptonic Medical (publ) – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar idag att sex veckor efter start av studien har 57 patienter startat behandling. Under juni månad beräknas ytterligare minst 13 patienter starta behandling. Syftet med studien är att undersöka effekten av Peptonic Medicals produktkandidat Vagitocin® (oxytocin) för behandling av vaginal atrofi […]

PEPTONIC medical deltar på Stora Aktiedagen i Stockholm den 7:e december

PEPTONIC medical (publ) (”Peptonic Medical eller ”Bolaget”)  – ett bolag som utvecklar läkemedel baserade på oxytocin – meddelar att bolaget kommer att delta på Stora Aktiedagen i Stockholm den 7:e december, plats Hotell Birger Jarl. Johan Inborr, verkställande direktör i Peptonic Medical, kommer att hålla en presentation kl 15.50. Deltagande är kostnadsfritt, men kräver anmälan […]

PEPTONIC medical AB (publ) deltar på Småbolagsdagen i Stockholm den 8:e juni

PEPTONIC medical (publ)  – ett bolag som utvecklar läkemedel baserade på oxytocin – kommer att delta på Småbolagsdagen i Stockholm den 8:e juni. Småbolagsdagen arrangeras av Redeye och Aktiespararna på Sheraton Hotell. PEPTONIC medicals verkställande direktör, Johan Inborr kommer att hålla en presentation kl 13.30. Presentationen sker på svenska och därefter deltar han i en […]

Kallelse till årsstämma i PEPTONIC medical AB (publ)

Aktieägarna i PEPTONIC medical AB (publ), org.nr 556776-3064 (”Bolaget”) kallas härmed till årsstämma torsdagen den 9 april 2015 kl. 16.30 i Gällöfsta Konferens lokaler, Biblioteksgatan 29, 114 35 Stockholm. Anmälan m.m. Aktieägare som önskar delta i årsstämman skall: dels vara införd i den av Euroclear Sweden AB förda aktieboken onsdagen den 1 april 2015, och […]

PEPTONIC medical (publ) progress towards next clinical study

PEPTONIC medical (publ) today announced it has engaged five study sites, all of them in Sweden, to participate in the next Phase 2b study and appointed A+ Science AB as the CRO to coordinate and monitor the study with PEPTONIC’s developmental estrogen-free product Vagitocin® in post-menopausal women. The enrollment of the first patient is due […]

VD-intervju publicerad i samband med första handelsdag på Aktietorget

Idag noteras PEPTONIC Medical på AktieTorget och i samband med det har VD, Dan Markusson, intervjuats av Redeye. Titta på intervjun » Aktiens handelsbeteckning är PMED. Aktiens ISIN-kod är SE0005962206. För ytterligare information om PEPTONIC medical AB (publ), vänligen kontakta: Dan Markusson, VD Telefon: 08-530 20 110 E-post: dan.markusson@peptonicmedical.se PEPTONIC medical AB (publ) är ett […]

PEPTONIC noteras på AktieTorget den 2 juli 2014

Peptonic har genomfört en riktad nyemission samt en spridningsemission under maj respektive juni månad som tillsammans tillför bolaget drygt 22 mkr före emissionskostnader. Efter de två emissionerna har bolaget ca 250 aktieägare, varav ca 200 tillkom i emissionerna. Bolaget står nu redo att starta sin planerade fas IIb studie samt att notera bolaget på AktieTorget […]

Road show calendar of PEPTONIC medical

PEPTONIC medical today announced the tentative program for company presentations during the subscription period for the rights issue in connection with the planned listing (IPO) on Aktietorget Stock Exchange (Stockholm) in June. May 27th – AktieTorget Uppsala June 3rd – AktieTorget Malmö June 4th – AktieTorget Göteborg June 9th – Småbolagsdagen Stockholm June 10th – […]

Nadia Whittley joins the PEPTONIC medical Board of Directors

PEPTONIC medical today announces that, at the PEPTONIC medical Annual General Meeting on April 8th, Mrs Nadia Whittley was elected as a new member to the Board of Directors. Mrs Whittley recently assumed the position as CEO of Pharmarama Ltd. (UK) and she has a long career in the pharmaceutical and medical device industry having […]

Resolutions from the Annual General Meeting

PEPTONIC medical (publ) today announced that the Annual General Meeting (AGM) on April 8th resolved to make the Company to a public company. In conjunction with this resolution, a rights issue was carried out resulting in an increased share capital from 297,098 SEK to 594,196 SEK. The AGM also resolved in favour of the Company […]

PEPTONIC medical (publ) recruits Business Development professional

PEPTONIC medical today announced that it has recruited Johan Inborr to lead the business development activities of the company on a consultancy basis. Johan is an experienced business development executive having held similar positions in pharmaceutical and medtech companies such as Medivir, Vironova and Carmeda with a long track record in in- and out-licensing, and […]

PEPTONIC medical raises SEK 6.9 million

PEPTONIC medical today announced that it has raised SEK 6.9 million in a directed private placement to existing and new shareholders. After the private placement, the number of shareholders in the company is 53. About PEPTONIC medical PEPTONIC medical is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal […]

First evaluation of VAGITOCIN® packaging completed

PEPTONIC medical today announced that it has completed the evaluation of different tube models and materials for use as primary packaging of VAGITOCIN® – the company’s oxytocin based gel in development for the treatment of vaginal atrophy. As a result of the 6-month stability tests, two tube variants have been found to meet the requirements […]

Last patient completed VAGITOCIN® PK study

PEPTONIC medical today announced that the last patient participating in the VAGITOCIN® pharmacokinetic (PK) study has been discharged after a final visit to the physician in accordance with the study protocol. The study has been carried out according to plan. Blood samples taken from the study subjects will be analysed at a laboratory in Gothenburg, […]

PEPTONIC medical in pre-IND meeting at FDA

PEPTONIC medical today announced that it met with the US Food and Drug Administration (FDA) earlier this month in a so called pre-IND meeting. The objectives of the meeting were to obtain FDA’s view on the clinical documentation generated to date and to seek advice regarding the continued clinical development of VAGITOCIN® towards a marketing […]

PEPTONIC work together with Destum partners

PEPONIC medical has signed an agreement with Destum Partners in USA for support in finding suitable collaboration partners. By using a US based consulting company the process to find collaboration partners in USA may be significantly facilitated. North America is the most important market for pharmaceuticals in the world. The collaboration with the mentioned company […]

PEPTONIC in collaboration with Clinartis

PEPTONIC has started a collaboration with Clinartis in USA. Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with planning of a so called pre-IND meeting with FDA (Food and Drug Administration). This meeting will help us in designing the phase III study and will also guide us for […]

Meeting with MPA

A regulatory/scientific, advisory meeting has been performed at the MPA on the 25.3.13. The results from the recently concluded clinical study and the design of the planned phase III were discussed. The advice from the MPA is not binding but gives a valuable direction how to continue the work. They were satisfied with our plans.

Approval of patent

A new formulation patent for oxytocin was approved by the Swedish patent authorities in February 2013. PEPTONIC has received a patent on the new formulation of Vagitocin. Sweden was the first country for submission of this patent. It was approved without any objections. A PCT application is now presented for patent rights in e.g. Europe, […]

PEPTONIC has raised 13.6 MSEK

PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK. During October 2012 a preference share emission was finished giving 13,6 MSEK. This constituted the possibilities for PEPTONIC to conclude the clinical dose-finding study, development of better application system, a new formulation for administration on the skin and for planning of the phase […]